Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a large increase in short interest in April. As of April 15th, there was short interest totaling 554,017 shares, an increase of 75.3% from the March 31st total of 316,118 shares. Based on an average daily trading volume, of 434,687 shares, the short-interest ratio is presently 1.3 days. Approximately 4.2% of the shares of the stock are short sold.

Insider Buying and Selling

In related news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was acquired at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the purchase, the insider directly owned 1,353,625 shares in the company, valued at approximately $1,813,857.50. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Acorn Wealth Advisors LLC purchased a new position in shares of Vivos Therapeutics during the fourth quarter worth approximately $30,000. XTX Topco Ltd purchased a new position in shares of Vivos Therapeutics during the second quarter worth approximately $65,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of Vivos Therapeutics during the second quarter worth approximately $220,000. DRW Securities LLC raised its stake in shares of Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after acquiring an additional 74,441 shares in the last quarter. Finally, Connective Capital Management LLC purchased a new position in shares of Vivos Therapeutics during the third quarter worth approximately $620,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. HC Wainwright cut their price target on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research note on Friday, April 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Monday, April 20th. Finally, Ascendiant Capital Markets cut their price target on shares of Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.58.

Vivos Therapeutics Trading Down 1.6%

VVOS stock opened at $0.85 on Wednesday. The company has a market capitalization of $11.46 million, a PE ratio of -0.41 and a beta of 6.93. Vivos Therapeutics has a one year low of $0.81 and a one year high of $7.95. The company’s 50 day moving average price is $1.26 and its two-hundred day moving average price is $1.86. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.24 and a current ratio of 0.24.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Wednesday, April 15th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.08). The business had revenue of $3.82 million for the quarter, compared to analysts’ expectations of $7.10 million. Vivos Therapeutics had a negative return on equity of 849.22% and a negative net margin of 121.37%.During the same period last year, the business posted ($2.22) earnings per share. As a group, analysts predict that Vivos Therapeutics will post -1.33 earnings per share for the current fiscal year.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.